Matthew Kurian, MD

Matthew Kurian: The first KYSCO webinar - OncoDaily Matthew Kurian: The first KYSCO webinar / cancer, CHI St. Joseph's Health, KYSCO webinar, Matthew Kurian, Neal Dunlap, Nicholas Burnett, OncoDaily, Oncology

The first KYSCO webinar - Matthew Kurian
@matthewkurianmd.bsky.social

oncodaily.com/blog/255763

#Cancer #CancerResearch #CancerTreatment #KYSCO #Webinar #Medicine #Health #Oncology #OncoDaily

Current AI programs miss the mark in my opinion. Some promising but a lot that needs to be improved!

🔍 Does AI reduce #clinician workload?

@NEJM study on @NuanceDragon DAX Copilot, an AI-powered documentation tool, found minimal impact on EHR efficiency & financial metrics❗️

💡AI tools need to be developed in comjuction with 🩺🥼🧑‍⚕️ not in silos
#AIinMedicine #LLMs @oncoalert.bsky.social

Jasmin Hundal: Day 2 at the San Antonio Breast Cancer Symposium was packed with insights - OncoDaily Jasmin Hundal: Day 2 at the San Antonio Breast Cancer Symposium was packed with insights / Amy Comander, Arya Roy, cancer, Jasmin Hundal, Matthew Kurian,

Day 2 at the San Antonio Breast Cancer Symposium was packed with insights - Jasmin Hundal

@sabcs.bsky.social
@jhundal.bsky.social
@aryaroy.bsky.social
@matthewkurianmd.bsky.social
@sabcs.bsky.social

oncodaily.com/insight/jasm...

#Cancer #OncoDaily #Oncology #SABCS24 #Medicine #Health

Unveiling the Latest in HER2+ Breast Cancer and Beyond With Drs Sara Hurvitz and Neil Iyengar Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer ...

Day 2 of OncLive News Network: On Location at #SABCS24 is ready for your viewing! Check out the #HER2 #bcsm updates from Drs Sara Hurvitz of @fredhutch.bsky.social & @neil-iyengarmd.bsky.social of @mskcancercenter.bsky.social hosted of course by Dr Chandler Park! www.onclive.com/view/unveili...

Fantastic event held yesterday by the @oncbrothers.bsky.social - truly thought provoking discussion with giants in the breast cancer space! Honored to be apart of it! @neil-iyengarmd.bsky.social @laurahuppert.bsky.so
@drsgraff.bsky.social
#sabcs2024 #signifymd

Wow! Median PFS was 44.3 months for pts treated with IBRANCE in combination with HP and endocrine therapy, and 29.1 months (95% CI: 23.3-38.6) for patients treated with HP and endocrine therapy alone [HR: 0.74 (95% CI, 0.58-0.94); p= 0.0074].

44 month first-line PFS!
@oncbrothers.bsky.social #SABCS

Congratulations to Dr. Ali for presenting @swog.org 0221 results at @sabcs.bsky.social @oncoalert.bsky.social @clevelandclinic.bsky.social

Great real world case discussion including #OSU @stoverlab.bsky.social @osuwexmed.bsky.social on the use of liquid biopsies in #mBC treatment decisions @sabcs.bsky.social #SABCS24 #bcsm Take Away - not ready for broad use in all pts, but may help in specific cases and holds promise for future

Fantastic results from EMBER-3 showing response with abemaciclib + imlunestrant with ORR of 35% in combination for ESR1m HR+ adjuvant and ABC patients and specifically showed in those with ESR1m ⬆️PFS from 11.1m to 5.5m with combo vs oral SERD alone. #sabcs2024 @breastcancerdoc.bsky.social

EMBER3 now in @NEJM highlights imlunestrant is better than fulvestrant in mESR1 MBC, and combo of abema+ imlumnestrant is better independent of mutations in all

Presentation soon @sabcs.bsky.social #SABCS24 Congrats @breastcancerdoc.bsky.social et al!

www.nejm.org/doi/full/10....

Dr. Dos Santos presents data around how the breast is changed during pregnancy...and persists (not just during pregnancy)! 🤰

May explain why parity and age impacts breast cancer risk 📊.

Early pregnancy ⬇️ breast cancer risk by 30-40%

#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
#bcsm

Need some simplification regarding ovarian suppression in premenopausal women? Nice summary by Prudence Francis from @petermaccc.bsky.social of who are candidates for OS + AI vs tamoxifen and timing of these agents is crucial! #sabcs2024

Planning your career after fellowship? Our article on ASCO connection explores the pros & cons of academia, community & hybrid practices! A practical guide to help fellows make informed decision! @matthewkurianmd.bsky.social Rajat Thawani!

Here at #SABCS24? Let’s discuss the current SoC & how the data will change/reinforce our practice from #SABCS24!

In Person, 📆: Dec11, 2024
⏰: 7:00-9:00PM
Register: bit.ly/aiosabcs24

#OncSky #AdvInOnc24 #bcsm
@drsarahsammons.bsky.social
@drgattimays.bsky.social
@drsgraff.bsky.social

Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor–Positive, Node-Positive Breast Cancer PURPOSEClinicopathological factors and the 21-gene Oncotype DX Breast Recurrence Score (RS) test both influence prognosis. Our goal was to develop a new tool, RSClinN+, to individualize recurrence ris...

RSclin for node positive ER+ patients is validated! I hope it’s available to use soon.

Always helpful to have tools to estimate recurrence and chemo benefit in these hard conversations with patients!

ascopubs.org/doi/10.1200/...

Dr. Abirami Natarajan and Dr. Sara Tolaney (@stolaney1.bsky.social) discuss adjuvant #ribociclib in this
Annals of Oncology editorial.
👀 check it out here:
sciencedirect.com/science/arti...

Congrats to all who’ve matched into heme/onc fellowship! Beginning of an exciting journey! If you are a future or current fellow deciding your career trajectory check out my commentary with colleagues as we discuss the differences in practice settings!

connection.asco.org/do/navigatin...

An outstanding group for those who are looking for the #OncSky Cancer Care community of professionals here on BlueSky. @oncoalert.bsky.social @pallonccop.bsky.social

Very vulnerable piece and really paints a great picture of today’s academic oncologist and trajectory of maybe others in a world where academics increasingly becomes more administrative and research focused.

Does this change your practice in terms of doing more neoadjuvant chemotherapy to downstage those more locally advanced HR+ tumors upfront and in premenopausal females?

I find this study very thought provoking and see the implications of financial toxicity with CDK4/6s, but are the patients we do this in ideally lower volume disease and bone only disease? Doing single agent AI for those with higher volume or visceral disease seems a bit risky to me practically.

Thanks for posting! A favorite activity is the recordings I do with Sara Tolaney around new data at our international meetings! @oncoalert.bsky.social @ucsfcancer.bsky.social

Good to see more and more organizations in alignment with starting at 40. Key point also is that everyone should be getting a breast cancer risk assessment starting at age 25 and reassessing periodically after to see if they are high risk and need earlier screening w additional modalities.

Vaginal Estrogen Therapy Use and Survival in Breast Cancer This cohort study compares the mortality risk associated with vaginal estrogen therapy vs no hormone replacement therapy in 2 cohorts of patients with breast cancer in Scotland and Wales.

Study in #JAMAOnc from Scotland/Wales of nearly 50k #breastcancer patients suggests vaginal estrogen use *NOT* associated w increase risk of breast cancer-specific mortality.

More reassuring data 👍

jamanetwork.com/journals/jam...

Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!